37173
document
Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukaemia : double-blind placebo controlled trial . A double-blind randomised trial compared 20 patients with leukaemia receiving human recombinant granulocyte macrophage colony stimulating factor ( GM CSF ) , with 20 patients receiving placebo for 14 days after allogeneic matched sibling bone marrow transplantation . The median neutrophil count at 14 days was significantly higher in the GM CSF group ( 1.90 vs. 0.46 x 10 ( 9 ) /l ) . The duration of hospital stay , the number of antibiotic days , and the number of fever days was the same for both patient groups . The lymphocyte count was significantly higher in the GM-CSF group than in the placebo group between days 10 and 15 after transplantation . The GM-CSF group had lower haemoglobin concentrations and platelets counts , and higher plasma urea creatinine and bilirubin , than the placebo group . There was no evidence that GM CSF was associated with a greater incidence of leukaemic relapse .
37174
Intervention_Physical
Human recombinant GM-CSF
37175
Intervention_Pharmacological
human recombinant granulocyte macrophage colony stimulating factor ( GM CSF )
37176
Intervention_Control
placebo
37177
Intervention_Physical
GM CSF
37178
Intervention_Pharmacological
GM-CSF
37179
Intervention_Control
placebo
37180
Intervention_Pharmacological
GM-CSF
37181
Intervention_Pharmacological
GM CSF
37182
Outcome_Physical
median neutrophil count
37183
Outcome_Physical
duration of hospital stay , the number of antibiotic days , and
37184
Outcome_Mental
the number of fever days
37185
Outcome_Physical
lymphocyte count
37186
Outcome_Physical
haemoglobin concentrations and platelets counts , and higher plasma urea creatinine and bilirubin
37187
Outcome_Physical
leukaemic relapse .
37188
Participant_Sample-size
20
37189
Participant_Condition
leukaemia
37190
Participant_Sample-size
20